| abstract |
Cancer vaccines are obtained by treating tumour cells or fibroblasts with a complex of DNA coding for an immunostimulating polypeptide, and of a DNA-binding substance, e.g. polylysine, which is preferably conjugated with transferrin. The complex also contains a conjugate of DNA-binding substance and an adenovirus. The adenovirus has at least one E4 defect or one E1a defect in combination with other gene defects. |